Significant progress on cornerstone program ABX464 (HIV and IBD)
Solid cash position, enabling the accomplishment of upcoming milestones until mid-2018
HIGHLIGHTS 2016
• Continued development of ABX464 showed encouraging results in HIV and inflammatory diseases ;
Discovery of new promising molecules targeting Chikungunya and Dengue; preclinical studies for Chikungunya ongoing ;
• Encouraging preclinical results in oncology with ABX196, Abivax’s proprietary immune enhancer ;
• ABX203 development suspended since mid-2016
• Bpifrance awarded a €8.4m milestone-based subsidy and loan from the “invest in the future” program ;
• Robust cost control and significant decrease in cash burn during second half 2016 (€5.1m during second half 2016 versus €11m during first half 2016) ;
• €23m available in cash as of December 31, 2016, allowing funding of the Company until mid-2018.
